Polaryx Therapeutics, Inc.
PLYX
$2.28
-$0.18-7.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 280.65% | -5.90% | 10.31% | 25.54% | -21.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.24% | 26.00% | 26.33% | -29.39% | 214.57% |
| Operating Income | 61.24% | -26.00% | -26.33% | 29.39% | -214.57% |
| Income Before Tax | 49.64% | -106.78% | -85.47% | 19.49% | 81.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.64% | -106.78% | -85.47% | 19.49% | 81.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.64% | -106.78% | -85.47% | 19.49% | 81.70% |
| EBIT | 61.24% | -26.00% | -26.33% | 29.39% | -214.57% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 52.68% | -73.37% | -53.69% | 36.87% | 89.89% |
| Normalized Basic EPS | 52.67% | -73.04% | -53.54% | 37.05% | 89.89% |
| EPS Diluted | 52.68% | -73.37% | -53.69% | 36.87% | 89.89% |
| Normalized Diluted EPS | 52.67% | -73.04% | -53.54% | 37.05% | 89.89% |
| Average Basic Shares Outstanding | 6.50% | 19.39% | 20.48% | 27.89% | 80.92% |
| Average Diluted Shares Outstanding | 6.50% | 19.39% | 20.48% | 27.89% | 80.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |